Cellectis (NASDAQ:CLLS) Issues Quarterly Earnings Results, Misses Expectations By $0.43 EPS

Cellectis (NASDAQ:CLLS) posted its earnings results on Thursday. The biotechnology company reported ($0.61) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.43), FiscalAI reports. Cellectis had a negative return on equity of 94.19% and a negative net margin of 102.34%. The company had revenue of $5.44 million during the quarter, compared to analyst estimates of $15.61 million.

Cellectis Stock Down 3.6%

Shares of Cellectis stock traded down $0.05 during trading on Thursday, reaching $1.33. The stock had a trading volume of 40,281 shares, compared to its average volume of 59,406. The company has a market capitalization of $133.45 million, a price-to-earnings ratio of -2.05 and a beta of 3.21. The stock has a fifty day moving average price of $1.53 and a two-hundred day moving average price of $2.95. The company has a current ratio of 1.37, a quick ratio of 1.37 and a debt-to-equity ratio of 1.61. Cellectis has a 52 week low of $0.88 and a 52 week high of $5.45.

Wall Street Analysts Forecast Growth

CLLS has been the subject of several recent research reports. Robert W. Baird cut their price target on Cellectis from $10.00 to $8.00 and set an “outperform” rating for the company in a report on Tuesday, September 15th. Wells Fargo & Company dropped their price objective on shares of Cellectis from $4.00 to $3.00 and set an “equal weight” rating for the company in a report on Tuesday, September 15th. Barclays cut Cellectis from an “overweight” rating to an “underweight” rating and cut their price target for the company from $9.00 to $1.30 in a report on Wednesday, September 16th. Weiss Ratings upgraded Cellectis from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, October 2nd. Finally, Citizens Jmp cut shares of Cellectis from an “outperform” rating to a “market perform” rating in a research report on Tuesday, September 15th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, two have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $5.46.

About Cellectis

Cellectis is a biotechnology company focused on developing gene-edited cell and gene therapies, with an emphasis on treatments for cancer. Founded in France in 1999, the company operates in France and the United States. Its research centers on TALEN gene-editing technology, which it uses to modify cells for potential therapeutic applications. Cellectis is developing allogeneic CAR T-cell therapies made from donor T cells, an approach intended to create treatments that can be prepared for use by multiple patients rather than made individually for each patient.